Critically, combinatorial targeting of TLR4 (TAK-242) and SPHK1 (PF-543) significantly enhanced TMZ efficacy, offering viable therapeutic approaches to overcome GBM chemoresistance (Fig. 8G). This evidence concerns the gene SPHK1 and glioblastoma.